Rituximab May Reduce IMN Proteinuria
Rituximab may decrease proteinuria in patients who have idiopathic membranous nephropathy (IMN) and severe nephrotic syndrome, according to investigators.
Fernando Fervenza, MD, of the Mayo Clinic in
Of the 14 patients who completed one year of follow-up, full remission was achieved in two and
partial remission achieved in six. Renal function remained stable in most patients. Reported side effects were minor and infusion related.
“This is the largest study to date to prospectively evaluate the effect of rituximab in patients with IMN,” the authors wrote. “In this study, rituximab appears to be effective in reducing proteinuria in a significant number of patients with IMN with severe nephrotic syndrome and relatively well-preserved renal function.”